Business Context and Reporting Period
Company: vTv Therapeutics Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 11, 2019
Event: Unregistered Sales of Equity Securities (Item 3.02)
Key Financial Metrics
This filing reports a specific capital raise event rather than periodic financial performance. The filing text does not provide clear values for revenue, profit, cash flow, margins, or total debt.
- Funds Raised: $1.0 million
- Shares Issued: 606,061 shares of Class A common stock
- Price Per Share: $1.65
- Investor: MacAndrews & Forbes Group LLC
Material Changes
The Company exercised its right under a March 18, 2019 Letter Agreement to require the Investor to purchase additional shares. This transaction increased the Company's cash position by $1.0 million and diluted existing shareholders by the issuance of 606,061 new shares.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure of the equity sale. The transaction was executed pursuant to definitive documentation referenced in a prior March 2019 filing.
Investor Verification Checklist
- Verify the terms of the March 18, 2019 Letter Agreement (Exhibit 10.2 to the March 20, 2019 8-K) to understand the full scope of the Investor's obligations.
- Confirm the total number of outstanding shares post-transaction to assess dilution impact.
- Review the Company's most recent 10-Q or 10-K for updated liquidity and cash burn rates, as this 8-K does not provide a full balance sheet.